Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel dual PPARgamma/delta agonist controls dyslipidemia and hyperglycemia in diabetes

Aug. 30, 2006

LCT seeks approval to begin phase I/II diabetes study of DiabeCell in patients

Aug. 29, 2006

TPM-02/Insulin successfully delivers insulin across skin

Aug. 28, 2006

ADA and EASD issue consensus statement on metformin treatment

Aug. 28, 2006

Targeting the pronociceptive action of CCK-8 for diabetes-induced peripheral sensitization

Aug. 28, 2006

Insulin-stimulating properties of Hon-Chi reported

Aug. 28, 2006

Diamyd shows efficacy in phase II type 1 diabetes study

Aug. 24, 2006

Novel antidiabetic compounds disclosed by Sirtris in recent patent

Aug. 23, 2006

Approvable letter for Arxxant

Aug. 22, 2006

NeuroSearch cleared to begin phase IIb obesity study of tesofensine

Aug. 22, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...